
Els Janssens
Els Janssens is a counsel in commercial law, litigation and healthcare regulatory issues in the Brussels office. Els worked as a senior regulatory legal counsel for Johnson & Johnson, supporting the company's global safety operations and advising on regulatory issues in relation to specific medicinal products. Els also worked as legal advisor for the European Medicines Agency, where she advised management, scientific committees, CMD(h) and the European Commission on a wide variety of issues in connection with authorisation procedures, submission requirements, pharmacovigilance obligations and procedures, as well as inspections. Based in Abu Dhabi from 2014 to 2019, she advised both multinational medical devices and pharmaceutical clients on healthcare regulations in the EU and UAE. Els advises multinational pharmaceutical clients and investors on healthcare regulations in the EU and UAE. She equally supports the Firm's global healthcare group with knowledge management for the healthcare sector. · Baker McKenzie BV/SRL
About
Els Janssens is a Counsel (senior associate equivalent) in the Brussels office of Baker McKenzie BV/SRL, focusing on commercial law, litigation, and healthcare regulatory issues. She previously worked as a senior regulatory legal counsel for Johnson & Johnson and as a legal advisor for the European Medicines Agency. Based in Abu Dhabi from 2014 to 2019, she advised multinational medical devices and pharmaceutical clients on EU and UAE healthcare regulations. She supports the firm's global healthcare group with knowledge management.
Practice areas
Office
Expertise
Education
- Catholic University of Leuven, Bachelor's Degree, 1994
- Erasmus University Rotterdam, M.C.L., 1996
- Catholic University of Leuven, License Political Science, 1997
- Catholic University of Leuven, Notary Public, 1998
- University of Lausanne, LL.M., 1999
- Université Catholique de Louvain, Selected courses in post-graduate education for industry pharmacist (regulatory affairs with respect to clinical trials and pharmaceutical legislation), 2005